| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000003218 |
| Receipt No. | R000003899 |
| Official scientific title of the study | To study the safety and efficacy of hypofractionated intensity modulated radiotherapy for patients with intermediate-risk prostate cancer. |
| Date of disclosure of the study information | 2010/04/01 |
| Last modified on | 2018/03/01 (Ver. 8) |
| Basic information | ||
| Official scientific title of the study | To study the safety and efficacy of hypofractionated intensity modulated radiotherapy for patients with intermediate-risk prostate cancer. | |
| Title of the study (Brief title) | To study the safety and efficacy of hypofractionated IMRT for patients with intermediate-risk prostate cancer. | |
| Region |
|
|
| Condition | |||
| Condition | prostate cancer | ||
| Classification by specialty |
|
||
| Classification by malignancy | Malignancy | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To study the safety and efficacy of hypofractionated intensity modulated radiotherapy of 70 Gy in 28 fractions for patients with intermediate-risk prostate cancer. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | The rate of late adverse effects at three years |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Historical |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Patients received 70Gy/28fxs to the prostate and the base of the seminal vesicle with IMRT. | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male | |||
| Key inclusion criteria | 1)Histologically confirmed prostate adenocarcinoma
2)One of the following combinations of factors: - Clinical stage T1b-2cN0M0, Gleason score 2-6, and prostate-specific antigen >10 but <20; - Clinical stage T1b-T2cN0M0, Gleason score 7, and prostate-specific antigen <20 3)ECOG-PS 0-1 4)No previous hormonal therapy or within 10 months after the start of hormonal therapy 5)Calcification in the prostate recognized on CT scans 6)Patients must sign informed consent form prior to registration |
|||
| Key exclusion criteria | 1) Small cell carcinoma
2) Previous or concurrent invasive cancers 3) Previous pelvic irradiation 4) Previous orchiectomy 5) Previous treatment of prostate cancer other than hormonal therapy 6) Cases judged by their physicians to be inappropriate as subjects |
|||
| Target sample size | 30 | |||
| Research contact person | |
| Name of lead principal investigator | Masahiko Oguchi M.D., Ph.D. |
| Organization | The Cancer Institute Hospital, Japanese Foundation for Cancer Research |
| Division name | Department of Radiation Oncology |
| Address | 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, JAPAN |
| TEL | 03-3520-0111 |
| oguchi@jfcr.or.jp | |
| Public contact | |
| Name of contact person | Takuyo Kozuka M.D., Ph.D. |
| Organization | The Cancer Institute Hospital, Japanese Foundation for Cancer Research |
| Division name | Department of Radiation Oncology |
| Address | 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, JAPAN |
| TEL | 03-3520-0111 |
| Homepage URL | |
| takuyo.kozuka@jfcr.or.jp | |
| Sponsor | |
| Institute | Department of Radiation Oncology, The Cancer Institute Hospita, the Japanese Fundation for Cancer Reseach |
| Institute | |
| Department | |
| Funding Source | |
| Organization | None |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Published |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000003899 |